MK-1468

• Description:

  MK-1468 is an orally active, selective, and BBB-permeable LRRK2 inhibitor. MK-1468 can be used for the research of Parkinson's disease[1][2].

• UNSPSC:

  12352005

• Target:

  LRRK2

• Type:

  Reference compound

• Related Pathways:

  Autophagy

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/mk-1468.html

• Purity:

  99.69

• Solubility:

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  ClC(C(N1CCN([C@]2([C@H](COC2)O)C)CC1)=C3)=CC(C=N4)=C3C=C4NC([C@@H]5C6(CCOCC6)C5)=O

• Molecular Formula:

  C26H33ClN4O4

• Molecular Weight:

  501.02

• References & Citations:

  [1]Kattar SD, et al. Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease. J Med Chem. 2023 Oct 20.|[2]Miller GK, et al. Effects of LRRK2 Inhibitors in Nonhuman Primates. Toxicol Pathol. 2023 Jul;51 (5) :232-245.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2769107-89-1]